scholarly journals Impact of NPS MedicineWise General Practitioner education programs and Choosing Wisely Australia recommendations on prescribing of Proton Pump Inhibitors in Australia

2019 ◽  
Author(s):  
Jianyun Wu ◽  
Scott Dickinson ◽  
Zain Elgebaly ◽  
Suzanne Gaye Blogg ◽  
Aine Heaney ◽  
...  

Abstract Background This study evaluated the impact of multifaceted NPS MedicineWise programs conducted in 2009 and 2015 that targeted general practitioners (GPs) to reduce unnecessary prescribing of proton pump inhibitors (PPIs). Methods Time series analyses of the dispensing rates of concessional PPI scripts between January 2006 and June 2016 using the Pharmaceutical Benefits Scheme (PBS) and Medicare Benefits Schedule (MBS) databases in Australia. Participants were GPs with dispensed PPI prescriptions to concessional patients between January 2006 and June 2016. The interventions were National NPS MedicineWise PPI educational programs in 2009 and 2015 delivered to all practising GPs in Australia. The 2015 intervention coincided with the release of Choosing Wisely Australia recommendations from the RACGP. Outcome measures included monthly dispensing rates of standard and low strength PPIs prescribed by GPs among concessional patients in Australia. Results Following the 2009 NPS MedicineWise program we observed a 6.7% reduction in the expected dispensing rate of standard strength PPIs among concessional patients between January 2006 and March 2015, and a total 8.6% reduction by June 2016 following the launch of the 2015 program. We observed a significant increase of 5.6% in the expected dispensing rate of low strength PPIs among concessional patients between April 2009 and March 2015, and no significant change in trend following the 2015 program. Conclusions The NPS MedicineWise programs were associated with reductions in the dispensing rate of standard strength PPIs, and with an increase in the dispensing rate of low-strength PPIs by June 2016. Although the rate of high-strength PPI prescribing is declining, these formulations still constitute the majority of PPI use in Australia. Regular interventions to sustain and improve PPI management by GPs may be warranted.

2019 ◽  
Author(s):  
Jianyun Wu ◽  
Scott Dickinson ◽  
Zain Elgebaly ◽  
Suzanne Gaye Blogg ◽  
Aine Heaney ◽  
...  

Abstract Background: This study evaluated the impact of multifaceted NPS MedicineWise programs conducted in 2009 and 2015 that targeted general practitioners (GPs) to reduce unnecessary prescribing of proton pump inhibitors (PPIs). Methods: Time series analyses was conducted of the dispensing rates of concessional PPI scripts between January 2006 and June 2016 using the Pharmaceutical Benefits Scheme (PBS) and Medicare Benefits Schedule (MBS) databases in Australia. Participants were GPs with dispensed PPI prescriptions to concessional patients between January 2006 and June 2016. The interventions were national NPS MedicineWise PPI educational programs in 2009 and 2015 delivered to all practising GPs in Australia. The 2015 intervention coincided with the release of Choosing Wisely Australia recommendations from the Royal Australian College of General Practitioners (RACGP). Outcome measures included monthly dispensing rates of standard and low strength PPIs prescribed by GPs among concessional patients in Australia. Results : Following the 2009 NPS MedicineWise program we observed a 6.7% reduction in the expected dispensing rate of standard strength PPIs among concessional patients between January 2006 and March 2015, and a total 8.6% reduction by June 2016 following the launch of the 2015 program. We observed a significant increase of 5.6% in the dispensing rate of low strength PPIs among concessional patients between April 2009 and March 2015, and no significant change in trend following the 2015 program. Conclusions: The NPS MedicineWise programs were associated with reductions in the dispensing rate of standard strength PPIs, and with an increase in the dispensing rate of low-strength PPIs by June 2016 although a causal relation was not confirmed. Although the rate of standard strength PPI prescribing is declining, these formulations still constitute the majority of PPIs used in Australia. Regular interventions to sustain and improve PPI management by GPs may be warranted.


2020 ◽  
Author(s):  
Jianyun Wu ◽  
Scott Dickinson ◽  
Zain Elgebaly ◽  
Suzanne Gaye Blogg ◽  
Aine Heaney ◽  
...  

Abstract Background: This study evaluated the impact of multifaceted NPS MedicineWise programs conducted in 2009 and 2015 that targeted general practitioners (GPs) to reduce unnecessary prescribing of proton pump inhibitors (PPIs). Methods: Time series analyses was conducted of the dispensing rates of concessional PPI scripts between January 2006 and June 2016 using the Pharmaceutical Benefits Scheme (PBS) and Medicare Benefits Schedule (MBS) databases in Australia. Participants were GPs with dispensed PPI prescriptions to concessional patients between January 2006 and June 2016. The interventions were national NPS MedicineWise PPI educational programs in 2009 and 2015 delivered to all practising GPs in Australia. The 2015 intervention coincided with the release of Choosing Wisely Australia recommendations from the Royal Australian College of General Practitioners (RACGP). Outcome measures included monthly dispensing rates of standard and low strength PPIs prescribed by GPs among concessional patients in Australia. Results : Following the 2009 NPS MedicineWise program we observed a 6.7% reduction in the expected dispensing rate of standard strength PPIs among concessional patients between January 2006 and March 2015, and a total 8.6% reduction by June 2016 following the launch of the 2015 program. We observed a significant increase of 5.6% in the dispensing rate of low strength PPIs among concessional patients between April 2009 and March 2015, and no significant change in trend following the 2015 program. Conclusions: The NPS MedicineWise programs were associated with reductions in the dispensing rate of standard strength PPIs and with an increase in the dispensing rate of low-strength PPIs by June 2016 although a causal relation was not confirmed. Although the rate of standard strength PPI prescribing is declining, these formulations still constitute the majority of PPIs used in Australia. Regular interventions to sustain and improve PPI management by GPs may be warranted.


2020 ◽  
Author(s):  
Jianyun Wu ◽  
Scott Dickinson ◽  
Zain Elgebaly ◽  
Suzanne Gaye Blogg ◽  
Aine Heaney ◽  
...  

Abstract Background: This study evaluated the impact of multifaceted NPS MedicineWise programs conducted in 2009 and 2015 that targeted general practitioners (GPs) to reduce unnecessary prescribing of proton pump inhibitors (PPIs). Methods: Time series analyses was conducted of the dispensing rates of concessional PPI scripts between January 2006 and June 2016 using the Pharmaceutical Benefits Scheme (PBS) and Medicare Benefits Schedule (MBS) databases in Australia. Participants were GPs with dispensed PPI prescriptions to concessional patients between January 2006 and June 2016. The interventions were national NPS MedicineWise PPI educational programs in 2009 and 2015 delivered to all practising GPs in Australia. The 2015 intervention coincided with the release of Choosing Wisely Australia recommendations from the Royal Australian College of General Practitioners (RACGP). Outcome measures included monthly dispensing rates of high/standard and low strength PPIs prescribed by GPs among concessional patients in Australia. Results : Following the 2009 NPS MedicineWise program we observed a 6.7% reduction in the expected dispensing rate of standard strength PPIs among concessional patients between January 2006 and March 2015, and a total 8.6% reduction by June 2016 following the launch of the 2015 program. We observed a significant increase of 5.6% in the dispensing rate of low strength PPIs among concessional patients between April 2009 and March 2015, and no significant change in trend following the 2015 program. Conclusions: The NPS MedicineWise programs were associated with reductions in the dispensing rate of high/standard strength PPIs and with an increase in the dispensing rate of low-strength PPIs by June 2016 although a causal relation was not confirmed. Although the rate of high/standard strength PPI prescribing is declining, these formulations still constitute the majority of PPIs used in Australia. Regular interventions to sustain and improve PPI management by GPs may be warranted.


2018 ◽  
Vol 108 ◽  
pp. 60-64 ◽  
Author(s):  
Miao Yan ◽  
Zhu-feng Wu ◽  
Dan Tang ◽  
Feng Wang ◽  
Yi-wen Xiao ◽  
...  

2019 ◽  
Vol 45 (08) ◽  
pp. 846-850 ◽  
Author(s):  
Tomáš Bolek ◽  
Matej Samoš ◽  
Ingrid Škorňová ◽  
Peter Galajda ◽  
Ján Staško ◽  
...  

AbstractDabigatran etexilate, a direct thrombin inhibitor, is now frequently used for long-term pharmacological prevention of stroke or systemic embolism in patients with atrial fibrillation. However, such long-term dabigatran therapy (DT) significantly increases the risk of upper gastrointestinal (GI) bleeding. This increased risk of gastric bleeds might be reduced with gastroprotective agents, such as proton pump inhibitors (PPIs). PPIs coadministrated with dabigatran reduce the risk of upper GI bleeding in patients on long-term oral DT. Nevertheless, there is heated discussion regarding interactions between PPI and dabigatran that lead to decreases in dabigatran plasma levels. This article reviews up to date data about the risk of gastric bleeding on dabigatran, the impact of PPI on the reduction of gastric bleeding, and the interaction between PPI and dabigatran leading to decreased dabigatran plasma levels.


2016 ◽  
Vol 111 ◽  
pp. S427-S428
Author(s):  
Pratima Dibba ◽  
Ankita Patel ◽  
Priya Mehta ◽  
Nadeem Wain ◽  
Sunya Ashraf ◽  
...  

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. e18732-e18732
Author(s):  
Manvi Sharma ◽  
Holly Michelle Holmes ◽  
Hemalkumar B Mehta ◽  
Hua Chen ◽  
Rajender R Aparasu ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document